Technology-driven educational modalities are increasingly utilized today in a variety of forms. Different combinations of the spectrum of simulation-based learning, the use of virtual reality, augmented reality, mixed reality, and serious gaming continue to gain traction on various educational platforms. In this paper, we share the formation of our project team to plan and execute a serious game on starting infusions and the use of infusion pump for nursing and health-care staff. The incorporation of element of assessment is also discussed. The various phases we went through included: Learning needs assessment and conceptualizationAssembly of project teamTransfer of medical conceptsStoryboard and content productionLearners' experiential mappingTesting of the prototypeBeta testing and release of the final product The collaborative work and coordination between the subject-matter experts together with the technical production team is critical. Issues such as assessment and debriefing in serious gaming were also addressed, not forgetting the need to ensure that, above all, learning must take place.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780635 | PMC |
http://dx.doi.org/10.4103/jets.jets_82_21 | DOI Listing |
J Infus Nurs
March 2025
Author Affiliations: Takeda Development Center Americas, Inc., Cambridge, Massachusetts (Kim Duff); IQVIA Clinical Research Organization, Milan, Italy (Arianna Soresini); IQVIA Clinical Research Organization, Cambridge, Massachusetts (Nancy Wolf* and Alane Fairchild); IQVIA Clinical Research Organization, Ankara, Turkey (Şükran Altan**); IQVIA Clinical Research Organization, Mexico City, Mexico (Wendy Bencomo); University Clinical Center of Serbia, Belgrade, Serbia (Ivana Ivankovic); University Health Network, University of Toronto, Toronto, Ontario, Canada (Evelyn Sarpong); IQVIA Clinical Research Organization, Warsaw, Poland (Anna Kuczkowska).
Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% offers potential improvements in patient independence and tolerability versus intravenous immunoglobulin (IVIG) when used for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). fSCIG 10% also requires less frequent infusions and fewer infusion sites than conventional subcutaneous immunoglobulin (subcutaneous immunoglobulin without hyaluronidase). The ADVANCE-CIDP 1 study demonstrated fSCIG 10% efficacy and safety in preventing CIDP relapse and positive responses from patients in terms of satisfaction and treatment preference.
View Article and Find Full Text PDFEur Heart J Case Rep
March 2025
Department of Pathology, Kayseri City Training and Research Hospital, 38080 Kayseri, Turkey.
Background: Lymphomas, which originate from the haematopoietic system, are seldom found in the heart due to the absence of a lymphoid system. Primary cardiac lymphoma is quite rare. Cardiac lymphomas can present with dyspnoea, heart failure, pericardial effusion, and arrhythmia.
View Article and Find Full Text PDFClin Cancer Res
March 2025
Memorial Sloan Kettering Cancer Center, New York City, NY, United States.
Purpose: Naxitamab is a humanized form of the murine anti-GD2 monoclonal antibody (mAb) 3F8. In an international trial, naxitamab+GM-CSF was effective against chemo-resistant high-risk neuroblastoma (HR-NB), leading to approval by the Food and Drug Administration. We now report results with patients in 1st complete remission (CR).
View Article and Find Full Text PDFFront Pharmacol
February 2025
Sarcomas and Rare Tumors Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Ifosfamide (IFO) is a nitrogen derivative used at different doses, alone or in combination, in the treatment of various types of solid and hematologic cancers. It is a pro-drug activated by cytochrome P450 enzymatic system into ifosforamide mustard, the alkylating component that carries out the cytotoxic effect of the IFO. The most common toxicities of IFO are gastrointestinal, cutaneous, hematological, urological, and neurological.
View Article and Find Full Text PDFWorld J Clin Pediatr
March 2025
Department of Anesthesiology and Intensive Therapy, Medicover Hospital, Bucharest 013982, Bucuresti, Romania.
Background: Cellular therapies have started an important new therapeutic direction in autistic spectrum disorder (ASD), and the ample diversity of ASD pathophysiology and the different types of cell therapies prompt an equally ample effort to employ clinical studies for studying the ASD causes and cell therapies. Stem cells have yielded so far mixed results in clinical trials, and at patient level the results varied from impressive to no improvement. In this context we have administered autologous cord blood (ACB) and a non-placebo, material intervention represented by an individualized combination of supplements (ICS) to ASD children.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!